Clinical Trial Update: Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept efficacy and safety study of eszopiclone (SEP-225441) for Generalized Anxiety Disorder has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• Lunesta (eszopiclone)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: COMPLETED | Results posted: 2015-08-21